Paul E. Marik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul E. Marik has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Varon
The University of Houston, Houston, Texas, USA
3 shared publications Danielle Kaplan
1 shared publicationGary P Zaloga
Methodist Research Institute, Indianapolis, IN 46202, USA
1 shared publicationKelly A. Wood
1 shared publicationMichael Pinsky
Department of Critical Care, University of Pittsburgh, Pittsburgh, USA
1 shared publicationMurugan Raghavan
Conemaugh Memorial Medical Center, Johnstown, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (29) , 3639-3649
Propofol: Therapeutic Indications and Side-Effects
Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w / v) propofol, 10% soyabean oil, 2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABAA receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant, has anti-inflammatory properties and is a bronchod ilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the “propofol syndrome”; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron tra nsport across the inner mitochondrial membrane.
- 1 November 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (29) , 3639-3649
Top Cited PapersPropofol: Therapeutic Indications and Side-Effects
Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w / v) propofol, 10% soyabean oil, 2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABAA receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant, has anti-inflammatory properties and is a bronchod ilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the “propofol syndrome”; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron tra nsport across the inner mitochondrial membrane.
- Top Cited Papers
Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis
Objective To compare the safety and clinical outcomes of enteral and parenteral nutrition in patients with acute pancreatitis. Data sources Medline, Embase, Cochrane controlled trials register, and citation review of relevant primary and review articles. Study selection Randomised controlled studies that compared enteral nutrition with parenteral nutrition in patients with acute pancreatitis. From 117 articles screened, six were identified as randomised controlled trials and were included for data extraction. Data extraction Six studies with 263 participants were analysed. Descriptive and outcome data were extracted. Main outcome measures were infections, complications other than infections, operative interventions, length of hospital stay, and mortality. The meta-analysis was performed with the random effects model. Data synthesis Enteral nutrition was associated with a significantly lower incidence of infections (relative risk 0.45; 95% confidence interval 0.26 to 0.78, P = 0.004), reduced surgical interventions to control pancreatitis (0.48, 0.22 to 1.0, P = 0.05), and a reduced length of hospital stay (mean reduction 2.9 days, 1.6 days to 4.3 days, P < 0.001). There were no significant differences in mortality (relative risk 0.66, 0.32 to 1.37, P = 0.3) or non-infectious complications (0.61, 0.31 to 1.22, P = 0.16) between the two groups of patients. Conclusions Enteral nutrition should be the preferred route of nutritional support in patients with acute pancreatitis.
Top Cited PapersMeta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis
Objective To compare the safety and clinical outcomes of enteral and parenteral nutrition in patients with acute pancreatitis. Data sources Medline, Embase, Cochrane controlled trials register, and citation review of relevant primary and review articles. Study selection Randomised controlled studies that compared enteral nutrition with parenteral nutrition in patients with acute pancreatitis. From 117 articles screened, six were identified as randomised controlled trials and were included for data extraction. Data extraction Six studies with 263 participants were analysed. Descriptive and outcome data were extracted. Main outcome measures were infections, complications other than infections, operative interventions, length of hospital stay, and mortality. The meta-analysis was performed with the random effects model. Data synthesis Enteral nutrition was associated with a significantly lower incidence of infections (relative risk 0.45; 95% confidence interval 0.26 to 0.78, P = 0.004), reduced surgical interventions to control pancreatitis (0.48, 0.22 to 1.0, P = 0.05), and a reduced length of hospital stay (mean reduction 2.9 days, 1.6 days to 4.3 days, P < 0.001). There were no significant differences in mortality (relative risk 0.66, 0.32 to 1.37, P = 0.3) or non-infectious complications (0.61, 0.31 to 1.22, P = 0.16) between the two groups of patients. Conclusions Enteral nutrition should be the preferred route of nutritional support in patients with acute pancreatitis.
- 1 May 2004
- Published by Springer Nature in Intensive Care Medicine
- Vol. 30 (5) , 748-756
Stress-hyperglycemia, insulin and immunomodulation in sepsis
Stress-hyperglycemia and insulin resistance are exceedingly common in critically ill patients, particularly those with sepsis. Multiple pathogenetic mechanisms are responsible for this metabolic syndrome; however, increased release of pro-inflammatory mediators and counter-regulatory hormones may play a pivotal role. Recent data suggests that hyperglycemia may potentiate the pro-inflammatory response while insulin has the opposite effect. Furthermore, emerging evidence suggests that tight glycemic control will improve the outcome of critically ill patients. This paper reviews the pathophysiology of stress hyperglycemia in the critically ill septic patient and outlines a treatment strategy for the management of this disorder.
- 1 May 2004
- Published by Springer Nature in Intensive Care Medicine
- Vol. 30 (5) , 748-756
Stress-hyperglycemia, insulin and immunomodulation in sepsis
Stress-hyperglycemia and insulin resistance are exceedingly common in critically ill patients, particularly those with sepsis. Multiple pathogenetic mechanisms are responsible for this metabolic syndrome; however, increased release of pro-inflammatory mediators and counter-regulatory hormones may play a pivotal role. Recent data suggests that hyperglycemia may potentiate the pro-inflammatory response while insulin has the opposite effect. Furthermore, emerging evidence suggests that tight glycemic control will improve the outcome of critically ill patients. This paper reviews the pathophysiology of stress hyperglycemia in the critically ill septic patient and outlines a treatment strategy for the management of this disorder.
- Top Cited Papers
Aspiration Pneumonia and Dysphagia in the Elderly
- 27 May 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (7) , 1035-1037
Aliens, anaerobes, and the lung!
- 27 May 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (7) , 1035-1037
Aliens, anaerobes, and the lung!
- 2 April 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (6) , 867-869
Death by parenteral nutrition
- 2 April 2003
- Published by Springer Nature in Intensive Care Medicine
- Vol. 29 (6) , 867-869
Death by parenteral nutrition
- Open Access
- 1 January 2003
- Published by Springer Nature in Critical Care
- Vol. 7 (5) , 374-84
Clinical review: The management of hypertensive crises
Hypertension is an extremely common clinical problem, affecting approximately 50 million people in the USA and approximately 1 billion individuals worldwide. Approximately 1% of these patients will develop acute elevations in blood pressure at some point in their lifetime. A number of terms have been applied to severe hypertension, including hypertensive crises, emergencies, and urgencies. By definition, acute elevations in blood pressure that are associated with end-organ damage are called hypertensive crises. Immediate reduction in blood pressure is required only in patients with acute end-organ damage. This article reviews current concepts, and common misconceptions and pitfalls in the diagnosis and management of patients with acutely elevated blood pressure.
- 1 January 2003
- Published by Springer Nature in Critical Care
- Vol. 7 (5) , 374-84
Open AccessClinical review: The management of hypertensive crises
Hypertension is an extremely common clinical problem, affecting approximately 50 million people in the USA and approximately 1 billion individuals worldwide. Approximately 1% of these patients will develop acute elevations in blood pressure at some point in their lifetime. A number of terms have been applied to severe hypertension, including hypertensive crises, emergencies, and urgencies. By definition, acute elevations in blood pressure that are associated with end-organ damage are called hypertensive crises. Immediate reduction in blood pressure is required only in patients with acute end-organ damage. This article reviews current concepts, and common misconceptions and pitfalls in the diagnosis and management of patients with acutely elevated blood pressure.